Home World News EMA Adopts a New Pharmaceutical Form of Selumetinib World News EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 486 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Patients With DCIS Reduce Risk Of Recurrence And Death If They... June 25, 2020 25-Year-Old Mom Had Chemo & Surgery, Then Was Told She Never... August 8, 2019 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma February 7, 2022 Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 Load more HOT NEWS Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ Man Offers Free Lawn Mowing Service To Elderly And Veterans A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival... EMA Recommends Extension of Therapeutic Indications for Cetuximab
